Nemaura Medical Inc. NMRD
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0002 Day range 0.0002
0.00001 52-week range 0.0005
- YTD
- 0.00%
- 1 year
- -50.00%
- Market cap
- 4.04K
- EPS (ttm)
- -0.39
- Shares out
- 40.35M
- Forward P/E
- -0.08
- YTD return
- 0.00%
- 1-year return
- -50.00%
- Volume
- 500
- Avg volume
- 426
- Open
- 0.0002
- Previous close
- 0.0001
- Day's range
- 0.0002 – 0.0002
- 52-week range
- 0.00001 – 0.0005
- Beta
- -0.03
- Analysts
- Buy
- Price target
- 1.50 (+1499900.0%)
- Earnings date
- Dec 23, 2024
2Y -0.0001 (-50.00%)
Key statistics
- Enterprise value
- 20.40M
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.07M
- Total cash
- 137.42K
- Total debt
- 19.64M
- Return on equity
- 0.00%
- Short % of float
- 0.31%
- 50-day average
- 0.03986
- 200-day average
- 0.098785
Analyst view
Consensus: buy
Buy
Price target (mean) 1.50
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate 0.00.
Financials — quick view
NMRD Revenue — quarterly 0
NMRD Net income — quarterly -1.20M
NMRD EPS — quarterly -0.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 11, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 12, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.10 | -0.11 | -0.01 | -10.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.14 | -0.09 | +0.05 | +35.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2023 | EF Hutton | main | Buy | Buy |
| Mar 29, 2023 | EF Hutton | reit | — | Buy |
| Feb 27, 2023 | EF Hutton | main | — | Buy |
| Feb 26, 2023 | HC Wainwright & Co. | main | — | Buy |
| Aug 18, 2022 | HC Wainwright & Co. | main | — | Buy |
About Nemaura Medical Inc.
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- nemauramedical.com
News
Reviewing InfuSystem (NYSE:INFU) and Nemaura Medical (OTCMKTS:NMRD) 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Important Update on Listing Status and Strategic Direction 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision 
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth 
12 Health Care Stocks Moving In Monday's After-Market Session 
Nemaura (NMRD) to Expand in UK With Metabolic Health Program 
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Your note
Sign in to keep a note on NMRD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GHADAR-GHADR ARASH | Chief Operating Officer | Purchase | Jan 4, 2024 | 100,000 |
| MCLARNEY JUSTIN JAMES | Chief Financial Officer | Stock Award(Grant) | Jan 30, 2022 | 22,293 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alyeska Investment Group, L.p. | 8.59% | 2,483,271 | 2.30M | Jun 29, 2023 |
| Vanguard Group Inc | 0.45% | 130,861 | 121.06K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.37% | 107,897 | 99.81K | Jun 29, 2023 |
| State Street Corporation | 0.19% | 53,666 | 49.65K | Jun 29, 2023 |
| Northern Trust Corporation | 0.09% | 26,737 | 24.73K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.03% | 7,328 | 6.78K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.44% | 126,682 | 117.19K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.23% | 67,468 | 33.66K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.05% | 15,517 | 7.74K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 11,700 | 5.84K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.02% | 7,006 | 3.50K | May 30, 2023 |
| Master Investment Portfolio-Diversified Equity Master Portfolio | 0.01% | 2,006 | 1.85K | Jun 29, 2023 |